
Dr Cherice Roth
Dr. Cherice Roth is a graduate of Texas A&M College of Veterinary Medicine. Along with her Doctorate she also holds a Master’s Degree in Biochemistry. She is currently the Chief Veterinary Officer of Digital Pet Health for Mars Veterinary Health, as well as Lead Medical Advisor for KeraVetBio and a board member for Seattle Humane Society, Board of Chief Veterinary Medical Officers (BCVMO) & Wallace Health. Dr. Roth is an author of children’s books. Her books, “What’s a REAL Doctor?” and “What does a REAL Doctor look like?” both focus on veterinary medicine, STEM, and representation within medical fields. She is also the author of the textbook, Virtual Veterinary Care and Telemedicine. She believes that veterinary virtual care is the answer for health disparities in pets, as well as part of the answer to psychological health issues of veterinary professionals. Outside of work, you can find her in the woods of Oregon with her many “Roth Ranch” animals, her sons (The Rothlings), and her husband, or serving on the medical board for several boxer, Doberman and dachshund charitable organizations.
In a market where acquisition costs are rising and patient expectations are evolving, the real battleground for DSOs is no longer just getting patients in the door — it’s keeping them. This session will showcase how leading DSOs are driving higher reappointment rates, stronger recall cycles, and consistent experiences; turning one-time visits into long-term patient relationships.
Predict churn and act before it happens
Automate smart reactivations using treatment history and patient preferences
Training clinical and front office teams to “own the relationship” not just the transaction
Today’s patients want more than appointment reminders — they want to feel known.
As DSOs scale, communication often becomes templated and transactional: generic texts, bulk emails, and one-size-fits-all outreach. But the most innovative DSOs are breaking that mold — using behavioral data, patient history, and automation to deliver personalized experiences at scale.
Build intelligent communication workflows that feel personal — even when automated
Align communication across SMS, email, and phone without overwhelming staff
Boost treatment acceptance, recall rates, and long-term loyalty through smart engagement
For DSOs with 10 to 100+ locations, the question is no longer “how do we reach patients?” — it's “how do we convert attention into booked appointments at the lowest possible cost?” In this session, hear how leading DSOs are engineering scalable, data-driven acquisition engines — integrating local market intelligence, central marketing oversight, and modern tech stacks to lower NPAC while increasing conversion.
The modern DSO’s marketing funnel: from awareness to conversion to reactivation
How to run geo-targeted, specialty-aligned campaigns at scale
Why tracking the full patient journey — not just lead volume — is now table stakes
How LTV modeling helps guide smarter acquisition decisions
It’s not just about growth — it’s about what kind of growth. Whether you're a single-location practice considering your first exit, or a 30-location DSO aiming to attract private equity interest, preparing for acquisition requires more than profitability and a clean P&L. In today’s deal environment, buyers are scrutinizing scalability, infrastructure, technology adoption, and operational sophistication more than ever.
What buyers are prioritizing right now (and what’s a red flag)
The difference between a “practice” and a “platform” in the eyes of PE
How to build acquirer-ready infrastructure: finance, compliance, tech, reporting
How digital maturity, clinical consistency, and patient retention drive valuation
Join GATC Health for an interactive roundtable exploring how AI-driven predictive intelligence is transforming investment strategy in drug development and biotech financing. Discover how the technology platform used by Lloyd's of London is now driving Derisq™ - a new report that delivers validated predictions of safety, efficacy, and non-obvious risk - predicting 11x more accurately than clinical trial outcomes - to provide confidence well before clinical trials begin.
In this session, investors and biopharma leaders will learn how:
- Predictive AI platforms can de-risk portfolios and prioritize high-probability assets
- Detailed predictions (91% specificity, 86% sensitivity) to drive capital efficiency and strategic decision-making
- Innovative risk mitigation approaches, including insurance-backed clinical outcomes through partnerships with Lloyd's of London, are creating new pathways to secure funding
Walk away with actionable insights on leveraging detailed predictive reports that deliver deep insights into unknown risk within 3-4 weeks to support your investment thesis and development strategy - reducing uncertainty and accelerating success.

V. Tyrone Lam

